Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

[Spironolactone in patients with resistant hypertension].

Rodilla E, Costa JA, Pérez-Lahiguera F, González C, Pascual JM.

Med Clin (Barc). 2008 Oct 4;131(11):406-11. Spanish.

PMID:
18928720
2.

Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?

Verdalles U, García de Vinuesa S, Goicoechea M, Macías N, Santos A, Perez de Jose A, Verde E, Yuste C, Luño J.

Nephrology (Carlton). 2015 Aug;20(8):567-71. doi: 10.1111/nep.12475.

PMID:
25818266
3.

Spironolactone and doxazosin treatment in patients with resistant hypertension.

Rodilla E, Costa JA, Pérez-Lahiguera F, Baldó E, González C, Pascual JM.

Rev Esp Cardiol. 2009 Feb;62(2):158-66. English, Spanish.

4.

Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.

Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA.

J Hypertens. 2016 May;34(5):1005-10. doi: 10.1097/HJH.0000000000000870.

5.
6.

[Role of antialdosteronics in the treatment of refractory hypertension].

Roca-Cusachs Coll A.

Med Clin (Barc). 2008 Oct 4;131(11):416-8. Spanish. No abstract available.

PMID:
18928722
7.

Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial.

Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Sep;158(3):384-90. doi: 10.5507/bp.2012.105. Epub 2012 Dec 7.

8.

Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.

Shlomai G, Sella T, Sharabi Y, Leibowitz A, Grossman E.

Hypertens Res. 2014 Dec;37(12):1037-41. doi: 10.1038/hr.2014.77. Epub 2014 Mar 27.

PMID:
24671013
9.

The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension.

Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Mar;157(1):50-5. doi: 10.5507/bp.2012.078. Epub 2012 Oct 31.

10.

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)--study protocol.

Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Husar R, Kocianova E, Taborsky M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Jun;155(2):143-8.

11.

Effects of spironolactone-altizide on left ventricular hypertrophy.

Degre S, Detry JM, Unger P, Cosyns J, Brohet C, Kormoss N.

Acta Cardiol. 1998;53(5):261-7.

PMID:
9922803
12.

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M.

Hypertension. 2011 Jun;57(6):1069-75. doi: 10.1161/HYPERTENSIONAHA.111.169961. Epub 2011 May 2. Erratum in: Hypertension. 2015 Feb;65(2):e7.

PMID:
21536989
13.

Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.

Oxlund CS, Cangemi C, Henriksen JE, Jacobsen IA, Gram J, Schousboe K, Tarnow L, Argraves WS, Rasmussen LM.

J Hum Hypertens. 2015 Jan;29(1):28-32. doi: 10.1038/jhh.2014.27. Epub 2014 Apr 17.

PMID:
24739800
14.

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.

Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP.

Expert Opin Pharmacother. 2008 Mar;9(4):509-15. doi: 10.1517/14656566.9.4.509.

PMID:
18312153
15.

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension.

Williams B, MacDonald TM, Caulfield M, Cruickshank JK, McInnes G, Sever P, Webb DJ, Salsbury J, Morant S, Ford I, Brown MJ.

BMJ Open. 2015 Aug 7;5(8):e008951. doi: 10.1136/bmjopen-2015-008951.

16.

Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.

Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA.

J Hum Hypertens. 2012 Aug;26(8):502-6. doi: 10.1038/jhh.2011.60. Epub 2011 Jun 16.

17.

Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators.

Hypertension. 2007 Apr;49(4):839-45. Epub 2007 Feb 19.

PMID:
17309946
18.

[And spironolactone in the treatment of heart failure?].

Sastre García F, García Bernabé C, López Reinoso C, Arribas Mir L.

Aten Primaria. 2000 Mar 15;25(4):281-2. Spanish. No abstract available.

20.

Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study.

Rosa J, Widimský P, Waldauf P, Zelinka T, Petrák O, Táborský M, Branny M, Toušek P, Čurila K, Lambert L, Bednář F, Holaj R, Štrauch B, Václavík J, Kociánová E, Nykl I, Jiravský O, Rappová G, Indra T, Krátká Z, Widimský J Jr.

J Hypertens. 2017 May;35(5):1093-1099. doi: 10.1097/HJH.0000000000001257.

PMID:
28118281

Supplemental Content

Support Center